Inhibition of human immunodeficiency virus type 1 reverse transcriptase, RNase H, and integrase activities by hydroxytropolones

被引:76
作者
Didierjean, J
Isel, C
Querré, F
Mouscadet, JF
Aubertin, AM
Valnot, JY
Piettre, SR
Marquet, R
机构
[1] Univ Strasbourg, IBMC, CNRS, UPR 9002, F-67084 Strasbourg, France
[2] Univ Rouen, IRCOF, CNRS, UMR 6014,Lab Fonct Azotees & Oxygenees Cpmplexes, F-76821 Mont St Aignan, France
[3] Ecole Normale Super, CNRS, LBPA, UMR 8113, F-94235 Cachan, France
[4] Univ Strasbourg, INSERM, UMR 544, Inst Virol, F-67000 Strasbourg, France
关键词
D O I
10.1128/AAC.49.12.4884-4894.2005
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Human immunodeficiency virus type I reverse transcriptase (RT) possesses distinct DNA polymerase and RNase H sites, whereas integrase (IN) uses the same active site to perform 3'-end processing and strand transfer of the proviral DNA. These four enzymatic activities are essential for viral replication and require metal ions. Two Mg2+ ions are present in the RT polymerase site, and one or two Mg2+ ions are required for the catalytic activities of RNase H and IN. We tested the possibility of inhibition of the RT polymerase and RNase H as well as the IN X-end processing and transfer activities of purified enzymes by a series of 3,7-dihydroxytropolones designed to target two Mg2+ ions separated by -3.7 angstrom The RT polymerase and IN 3' processing and strand transfer activities were inhibited at submicromolar concentrations, while the RNase H activity was inhibited in the low micromolar range. In all cases, the lack of inhibition by tropolones and O-methylated 3,7-dihydroxytropolones was consistent with the active molecules binding the metal ions in the active site. In addition, inhibition of the DNA polymerase activity was shown to depend on the Mg2+ concentration. Furthermore, selective inhibitors were identified for several of the activities tested, leaving some potential for design of improved inhibitors. However, all tested compounds exhibited cellular toxicity that presently limits their applications.
引用
收藏
页码:4884 / 4894
页数:11
相关论文
共 55 条
[1]  
Arts EJ, 1998, PROG NUCLEIC ACID RE, V58, P339
[2]   Inhibition of the ribonuclease H and DNA polymerase activities of HIV-1 reverse transcriptase by N-(4-tert-butylbenzoyl)-2-hydroxy-1-naphthaldehyde hydrazone [J].
Borkow, G ;
Fletcher, RS ;
Barnard, J ;
Arion, D ;
Motakis, D ;
Dmitrienko, GI ;
Parniak, MA .
BIOCHEMISTRY, 1997, 36 (11) :3179-3185
[3]   Selective inhibition of HIV-1 reverse transcriptase-associated ribonuclease H activity by hydroxylated tropolones [J].
Budihas, SR ;
Gorshkova, I ;
Gaidamakov, S ;
Wamiru, A ;
Bona, MK ;
Parniak, MA ;
Crouch, RJ ;
McMahon, JB ;
Beutler, JA ;
Le Grice, SFJ .
NUCLEIC ACIDS RESEARCH, 2005, 33 (04) :1249-1256
[4]   Binding of different divalent cations to the active site of avian sarcoma virus integrase and their effects on enzymatic activity [J].
Bujacz, G ;
Alexandratos, J ;
Wlodawer, A .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (29) :18161-18168
[5]   Crystal structure of the HIV-1 integrase catalytic core and C-terminal domains: A model for viral DNA binding [J].
Chen, JCH ;
Krucinski, J ;
Miercke, LJW ;
Finer-Moore, JS ;
Tang, AH ;
Leavitt, AD ;
Stroud, RM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (15) :8233-8238
[6]   Structure and function of HIV-1 integrase [J].
Chiu, TK ;
Davies, DR .
CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2004, 4 (09) :965-977
[7]   DIVALENT-CATION MODULATION OF THE RIBONUCLEASE FUNCTIONS OF HUMAN-IMMUNODEFICIENCY-VIRUS REVERSE-TRANSCRIPTASE [J].
CIRINO, NM ;
CAMERON, CE ;
SMITH, JS ;
RAUSCH, JW ;
ROTH, MJ ;
BENKOVIC, SJ ;
LEGRICE, SFJ .
BIOCHEMISTRY, 1995, 34 (31) :9936-9943
[8]   CRYSTAL-STRUCTURE OF THE RIBONUCLEASE-H DOMAIN OF HIV-1 REVERSE-TRANSCRIPTASE [J].
DAVIES, JF ;
HOSTOMSKA, Z ;
HOSTOMSKY, Z ;
JORDAN, SR ;
MATTHEWS, DA .
SCIENCE, 1991, 252 (5002) :88-95
[9]   HIV-chemotherapy and -prophylaxis: new drugs, leads and approaches [J].
De Clercq, E .
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2004, 36 (09) :1800-1822
[10]   Antiviral drugs in current clinical use [J].
De Clercq, E .
JOURNAL OF CLINICAL VIROLOGY, 2004, 30 (02) :115-133